GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laboratorios Farmaceuticos Rovi SA (XMAD:ROVI) » Definitions » PEG Ratio

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) PEG Ratio : 0.57 (As of May. 20, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Laboratorios Farmaceuticos Rovi PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Laboratorios Farmaceuticos Rovi's PE Ratio without NRI is 32.76. Laboratorios Farmaceuticos Rovi's 5-Year EBITDA growth rate is 57.50%. Therefore, Laboratorios Farmaceuticos Rovi's PEG Ratio for today is 0.57.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Laboratorios Farmaceuticos Rovi's PEG Ratio or its related term are showing as below:

XMAD:ROVI' s PEG Ratio Range Over the Past 10 Years
Min: 0.14   Med: 3.94   Max: 313.42
Current: 0.57


During the past 13 years, Laboratorios Farmaceuticos Rovi's highest PEG Ratio was 313.42. The lowest was 0.14. And the median was 3.94.


XMAD:ROVI's PEG Ratio is ranked better than
80.36% of 112 companies
in the Biotechnology industry
Industry Median: 1.66 vs XMAD:ROVI: 0.57

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Laboratorios Farmaceuticos Rovi PEG Ratio Historical Data

The historical data trend for Laboratorios Farmaceuticos Rovi's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laboratorios Farmaceuticos Rovi PEG Ratio Chart

Laboratorios Farmaceuticos Rovi Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 285.17 2.24 0.70 0.14 0.30

Laboratorios Farmaceuticos Rovi Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.17 0.21 0.30 -

Competitive Comparison of Laboratorios Farmaceuticos Rovi's PEG Ratio

For the Biotechnology subindustry, Laboratorios Farmaceuticos Rovi's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laboratorios Farmaceuticos Rovi's PEG Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Laboratorios Farmaceuticos Rovi's PEG Ratio falls into.



Laboratorios Farmaceuticos Rovi PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Laboratorios Farmaceuticos Rovi's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=32.757966616085/57.50
=0.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


Laboratorios Farmaceuticos Rovi  (XMAD:ROVI) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Laboratorios Farmaceuticos Rovi PEG Ratio Related Terms

Thank you for viewing the detailed overview of Laboratorios Farmaceuticos Rovi's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Business Description

Traded in Other Exchanges
Address
Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.